ArticleJournal of health economics and outcomes research2024
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.
Article in Journal of health economics and outcomes research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer.The Journal of clinical investigation · 2026Article
- Bridging the evidence gap: three-year BCG maintenance therapy shows enhanced protection over one-year regimen in Chinese NMIBC.World journal of surgical oncology · 2026Article
- Clinical Outcomes in Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer.JAMA network open · 2026Article
- Article
- Knowledge, attitudes, and practices related to health management among patients receiving intravesical instillation.Frontiers in oncology · 2026Article
- Decoding the temporal dimension of innate immunity in intravesical BCG therapy.Frontiers in immunology · 2026Article
- Therapeutic and prognostic value of repeat transurethral resection for high-grade Ta bladder cancer: a propensity score matching analysis.American journal of cancer research · 2026Article
- Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure: a systematic review.BMJ oncology · 2026Article
- Traditional Chinese medicine in non-muscle-invasive bladder cancer: a scoping review of syndrome characteristics and critical synthesis of pharmacological and mechanistic evidence.Frontiers in pharmacology · 2026Review
- Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guérin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German health claims data.World journal of urology · 2025Article
- Real-world use of maintenance bacillus Calmette-Guérin therapy in patients with non-muscle-invasive bladder cancer in Japan: ASUKA study.BJUI compass · 2025Article
- Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.Cancer medicine · 2025Review
- Therapeutic Advances in Bladder Preservation for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.